Home » Clinical Trials »  Search Clinical Trials

Therapeutic Areas:  |  Hematology  |  Oncology

Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters
 

Chronic Myeloid Leukemia Clinical Trials

A listing of Chronic Myeloid Leukemia medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

RESULTS

Found (4) clinical trials

Everolimus Cytarabine and Daunorubicin in Treating Patients With Relapsed Acute Myeloid Leukemia

OBJECTIVES: Primary - Determine the maximum tolerated dose of everolimus. - Determine the toxicity of this regimen. Secondary - Assess the activation of PI3K/AKT and mTORC 1 in leukemic blasts. - Evaluate the pharmacokinetics of everolimus at different concentrations. OUTLINE: This is a multicenter study. Patients receive primary induction therapy ...

Phase

Laboratory-Treated Peripheral Blood Cell Infusion After Donor Stem Cell Transplant in Treating Patients With Hematologic Cancers or Other Diseases

OBJECTIVES: Primary - Establish the feasibility of delayed infusion of ex vivo anergized donor peripheral blood mononuclear cells (PBMC) after CD34-selected megadose haploidentical hematopoietic stem cell transplantation (HSCT) in patients with hematopoietic cancers or other diseases. - Determine the feasibility of collecting parental allogeneic stimulator cells to induce anergy to ...

Phase

Anti-CD45 Monoclonal Antibody Cytarabine Cyclophosphamide and Total-Body Irradiation With or Without Alemtuzumab in Treating Patients Undergoing a Donor Stem Cell Transplant For Advanced Leukemia or Other Hematologic Cancer

OBJECTIVES: Primary - To evaluate the toxicity and the anti-tumor activity of anti-CD45 monoclonal antibody in patients with relapsed or resistant leukemia or other hematologic malignancy undergoing allogeneic stem cell transplantation. Secondary - To describe the effects of anti-CD45 on normal hematopoiesis and on complement levels. - To describe the ...

Phase

Natural Killer Cells and Bortezomib to Treat Cancer

Natural killer (NK) cells are innate immune lymphocytes that are identified by the expression of the CD56 surface antigen and the lack of CD3. Unlike antigen specific T cells, NK cells do not require the presence of a specific tumor antigen for the recognition and killing of cancer cells. Our ...

Phase